文献速递中枢神经肿瘤放疗放疗物理与技术

脑转移瘤患者接受MR引导下分次立体定向放疗的探索性分析

An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-02-23

28例脑转移瘤患者(共88个病灶)在1.5 T MR-Linac上接受30 Gy/5次的分次立体定向放疗,每日MR扫描并重新优化计划。分次间肿瘤体积显著缩小,有瘤周水肿或多发病灶者分次间变化更明显;自适应计划全部140次均满足靶区覆盖要求,且全脑剂量低于非自适应计划。

要点

  • 28例脑转移瘤患者88个病灶接受30 Gy/5次FSRT,每日MR引导重新优化计划。
  • 分次间肿瘤体积较模拟定位时显著缩小,Fx5中位相对体积变化为-27.73%。
  • 非自适应计划26/140次(19%)靶区覆盖低于处方,自适应计划140次全部达标。

核心结论

  • 脑转移瘤患者在1.5 T MR-Linac上接受FSRT期间可观察到显著的分次间肿瘤变化。
  • 每日MR引导下的治疗计划重新优化对有瘤周水肿或多发病灶的患者显示出剂量学获益。

研究设计与样本

  • 探索性分析,连续纳入28例脑转移瘤患者,在1.5 T MR-Linac上接受30 Gy/5次的分次立体定向放疗。
  • 每日MR扫描用于生成自适应计划,并在模拟定位(Fx0)及所有分次(Fx1至Fx5)的MR图像上勾画脑病灶及瘤周水肿以评估分次间变化。
  • 采用绝对/相对体积、Dice相似系数(DSC)和Hausdorff距离(HD)指标量化变化,并比较非自适应与自适应计划的计划靶区(PTV)覆盖和危及器官(OAR)约束。

主要发现

  • 共评估28例患者的88个病灶,其中23例(23/28,82.1%)为原发性肺腺癌。
  • 全部88个病灶在FSRT期间较Fx0出现显著肿瘤体积缩小,Fx1至Fx5的中位相对体积变化分别为-0.75%、-5.33%、-9.32%、-17.96%和-27.73%(p < 0.05)。
  • 47个(47/88,53.4%)病灶伴有瘤周水肿,其分次间变化与无瘤周水肿病灶相比有显著差异(p < 0.001)。
  • 多发病灶患者(13/28,46.4%)的分次间肿瘤变化较单病灶患者(15/28,53.6%)更显著,包括肿瘤体积缩小和解剖移位(p < 0.001)。
  • 非自适应计划中26/140次(19%)的PTV覆盖低于处方覆盖,其中12次(9%)低于处方超过10%;全部140次自适应计划均满足处方靶区覆盖,且自适应计划的全脑剂量低于非自适应计划(p < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T MR-Linac. The FSRT fractions employed daily MR scans and the contours were utilized to create each adapted plan. The brain lesions and perilesional edema were delineated on MR images of pre-treatment simulation (Fx0) and all fractions (Fx1, Fx2, Fx3, Fx4 and Fx5) to evaluate the inter-fractional changes. These changes were quantified using absolute/relative volume, Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics. Planning target volume (PTV) coverage and organ at risk (OAR) constraints were used to compare non-adaptive and adaptive plans. RESULTS: A total of 28 patients with 88 lesions were evaluated, and 23 patients (23/28, 82.1%) had primary lung adenocarcinoma. Significant tumor volume reduction had been found during FSRT compared to Fx0 for all 88 lesions (median -0.75%, -5.33%, -9.32%, -17.96% and -27.73% at Fx1, Fx2, Fx3, Fx4 and Fx5, p < 0.05). There were 47 (47/88, 53.4%) lesions being accompanied by perilesional edema and the inter-fractional changes were significantly different compared to those without perilesional edema (p < 0.001). Patients with multiple lesions (13/28, 46.4%) had more significant inter-fractional tumor changes than those with single lesion (15/28, 53.6%), including tumor volume reduction and anatomical shift (p < 0.001). PTV coverage of non-adaptive plans was below the prescribed coverage in 26/140 fractions (19%), with 12 (9%) failing by more than 10%. All 140 adaptive fractions met prescribed target coverage. The adaptive plans also had lower dose to whole brain than non-adaptive plans (p < 0.001). CONCLUSIONS: Significant inter-fractional tumor changes could be found during FSRT in patients with BMs treated on the 1.5 T MR-Linac. Daily MR-guided re-optimization of treatment plans showed dosimetric benefit in patients with perilesional edema or multiple lesions.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ding S, Liu B, Zheng S, et al. An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases. Clin Transl Radiat Oncol. 2023. PMID: 36910023. doi:10.1016/j.ctro.2023.100602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。